Detalle Publicación


Pomalidomide, cyclophosphamide, and dexamethasone for the treatment of relapsed/ refractory multiple myeloma: real-world analysis of the pethema-GEM experience

Autores: Rodríguez Otero, Paula (Autor de correspondencia); Sirvent, M.; González-Rodríguez, A. P.; Lavilla, E.; García de Coca, A.; Arguiñano, J. M.; Martí, J. M.; Cabañas, V.; Motllo, C.; de Cabo, E.; Encinas, C.; Murillo, I.; Hernández-Rivas, J. A.; Pérez-Persona, E.; Casado, F.; Sampol, A.; García, R.; Blanchard, M. J.; Anguita, M.; Paz Lafuente, A.; Inigo, B.; López, A.; Ribas, P.; Arnao, M.; Maldonado, R.; Blade, J.; Mateos, M. V.; Lahuerta, J. J.; San Miguel Izquierdo, Jesús
ISSN: 2152-2650
Volumen: 21
Número: 6
Páginas: 413 - 420
Fecha de publicación: 2021
Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging. We analyzed the efficacy and safety of pomalidomide, cyclophosphamide, and dexamethasone (PomCiDex) in a real-world RRMM population. Median progression-free and overall survival were 7.6 and 12.6 months, respectively, which compares favorably with other triplets in the same setting. PomCiDex remains a manageable, cost-effective, and all-oral triplet combination for RRMM. Introduction: Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging, especially for patients with disease refractory to initial therapy, and in particular for disease developing refractoriness to lenalidomide. Indeed, with currently approved treatments, median progression-free survival (PFS) in the lenalidomide-refractory setting is less than 10 months, reflecting the difficulty in treating this patient population. Pomalidomide is a second-generation immunomodulatory drug that has shown activity in lenalidomide-refractory disease in the setting of different combinations. Patients and Methods: A real-world study was conducted by the Spanish Myeloma group in a cohort of patients with RRMM treated with pomalidomide, cyclophosphamide, and dexamethasone (PomCiDex). One hundred patients were treated with a median of 3 prior lines of therapy. Results: Overall response rate was 39%, with a clinical benefit rate of 93%. Median PFS was 7.6 months; median overall survival (OS) was 12.6 months. Median PFS and OS survival were consistent across the different subgroups analyzed. Prolonged PFS and OS were found in patients with responsive disease. Conclusion: Our results compared favorably with those obtained with different pomalidomide-based combinations in a similar patient population. PomCiDex remains a manageable, cost-effective, and all-oral triplet combination for RRMM patients. (C) 2021 Published by Elsevier Inc.